BioSpace News Archive

Palisade Bio, Inc., a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, summarized the Company’s recent corporate developments and reported its financial results for the second quarter 2023.

INVO Bioscience, Inc., a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture procedure it enables, announced it has closed the previously announced acquisition of Wisconsin Fertility Institute.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Neema Mayhugh, PhD to its Board of Directors.

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023.

Biotricity Inc., a Technology-as-a-Service company operating in the remote cardiac monitoring sector of consumer healthcare, is pleased to report that its business continues to demonstrate strong fundamentals that are propelling the Company towards profitability.

Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has filed its quarterly report for the 2023 second quarter.

Neurophth Therapeutics, Inc. (“Neurophth”), a China’s leading gene therapy company for ophthalmic diseases, announced the closing of nearly 95 million USD in Series C+ financing

CAS and Molecule.one have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules.

PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).

Molecular Templates, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company’s common stock at a special meeting of the Company held on August 11, 2023.